高血壓 高尿酸 慢性腎病 胰島素 https://2019medicinenote.blogspot.com/2019/12/blog-post_57.html . 糖尿病相關筆記~目錄 https://2019medicinenote.blogspot.com/2020/01/blog-post_4.html

2020年3月18日 星期三

Gemfibrozil和Fenofibrate的比較

臨床藥物治療學 102-03-13 高血脂症的防治觀念與用藥選擇
Gemfibrozil和Fenofibrate的比較

FDA 2016-04-19最新報告指出,從ACCORD study做出的結論,statins與fibrate並用,跟單純使用Statins相比,在糖尿病患中,兩者的心血管疾病發生並無不同。另外,根據AIM-HIGH study指出,statins與niacin併用與statins單獨使用相比,雖然可以改善HDL以及TG,但是對於心血管疾病和改善LDL並沒有明顯差別,而HPS2-THRIVE study也同樣指出statins與niacin同時使用,與單用statins相比,並不會更改善心血管疾病的發生,所以FDA取消了statins + fibrate
以及statin + niacin的合併劑型。

不建議併用 repaglinide (novonorm 諾和隆) 及 gemfibrozil, 此兩藥併用會增加低血糖風險,在歐洲是禁止同時使用這兩種藥物。如有需要使用 fibrate 類 藥物,可以選擇將 gemfibrozil 改為 fenofibrate。

三酸甘油酯的控制 Control of hyper-triglycemia

臨床藥物治療學 102-03-13 高血脂症的防治觀念與用藥選擇
Triglyceral TG 三酸甘油酯的控制
第2型糖尿病人最常見之血脂異常為:
1. 三酸甘油酯升高, 糖尿病造成的三酸甘油酯升高通常小於400 mg/dL,若大於400mg/dL應考慮其他次發的原因。
2. 高密度膽固醇下降。

對於糖尿病合併高三酸甘油酯患者
1、TG介於200~400 mg/dL 首要之治療方向為嚴格控制血糖,及飲食控制、減重、運動、減少酒精的攝食等。嚴格控制血糖對降TG非常有效,應先積極嘗試,單獨使用胰島素或併用胰島素增敏劑控制血糖對降TG也有效,如果效果不彰,才考慮使用降血脂藥物治療。
2、TG>400 mg/dL應考慮同時使用降血脂藥物治療以降低併發急性胰臟炎之風險。
a.TG及LDL均高可單獨使用高劑量的Statins,因高劑量的Statins除了降LDL外,同時也可降TG達30 %以上。如果是使用Fibric acid類藥物,可嘗試單獨使用Fenofibrate,此藥對TG跟LDL同時有效,但不可單獨使用Gemfibrozil
b.LDL不高且TG超過400 mg/dL,使用降TG類藥物(如Fibrate)會較有效,此時則建議使用Gemfibrozil。
3、病人TG嚴重升高:
>1,000 mg/dL:美國糖尿病學會定義標準,>500 mg/dL:美國NCEP-ATP-III及我國衛生署定義標準因有急性胰臟炎的風險,必須馬上使用F ibrate類降血脂藥物治療,Gemfibrozil為首選,同時施以嚴格之非藥物治療,包括低脂飲食(佔總熱量10%)、減重、及加強運動。三酸甘油酯的控制

各類藥物對於降血脂能力之比較

依據健保給付的規定,使用降血脂藥物的病人,第1年應每3-6個月抽血檢查1次,第2年以後應至少每6-12個月抽血檢查1次。
降低LDL-C效果以 rosuvastatin 最強


臨床藥物治療學 102-03-13 高血脂症的防治觀念與用藥選擇
Statin類. 
1. 慢性肝疾病患者:選用 pravastatin 或rosuvastatin (親水性),並從低劑量開始
2. 嚴重腎功能不佳患者(Clcr <30 mL/min):可選擇 atorvastatin 或fluvastatin (不需調整劑量)
3.代謝酵素:
(1) 經CYP3A4:Atorvastain、lovastatin、simvastatin;
(2) 經 CYP2C9:Fluvastatin、rosuvastatin;
(3) Pravastain 經硫化代謝
4.建議接受治療後3個月監測肝功能,之後應定期追蹤
5.懷孕分級:X
其他降血脂藥物能力比較

Pitavastatin 




酒精及藥物對於血脂肪的影響

臨床藥物治療學  2012-03-31 高血脂症的用藥觀念與防治選擇
酒精會增加TG, 但對LDL影響不大


老年人血壓 血脂肪 血糖控制目標

活動力佳的, 可以比照一般成人
活動力差的, 預期餘命短的, 不需要太積極


2020年3月17日 星期二

胸部X光診斷肺炎有時候不容易看出來

在祕密花園看到的, 連結裡面有連續的CT可以看.
.
70-year-old male with proven COVID-19. Imaging reveals bilateral areas of peripheral ground-glass opacity.
https://bit.ly/2WhZNwY
Case contributed by Dr Fabio Macori.


腎臟尿酸結石治療

避免腎臟發生尿酸結石的方法有三種
鹼化尿液
增加水分補充
減少尿酸生成

TREATMENT
Because alkalinization of the urine with medical therapy can lead to dissolution of pure uric acid stones, more invasive procedures (such as extracorporeal shock wave lithotripsy) are usually not required. The three treatments options to prevent recurrent uric acid nephrolithiasis include [3]:
●Alkalinization of the urine
●Increased fluid intake
●Reduction of uric acid production with reduced purine intake and xanthine oxidase inhibitors

尿酸腎結石病患都應該鹼化尿液及增加水分補充
Urinary alkalinization and increased fluid intake should be prescribed to almost all patients with uric acid stones. The indications for xanthine oxidase inhibitors to reduce uric acid production depend upon whether uric acid stones are recurrent despite alkalinization or when alkalinization cannot be used and also upon the presence or absence of gout:

Xanthine Oxidase  inhibitor  主要用於鹼化尿液和補充水分治療無效的病患, 尿酸生成過多 (每天超過 1000 mg) 的病患, 鹼化尿液和補充水分可能無效, 但尿酸排泄在正常範圍內的病患,  xanthine oxidase inhibitor 仍有效
●Recurrent uric acid stones – Xanthine oxidase inhibitors are usually reserved for patients who continue to have stones despite urinary alkalinization and a prescribed higher fluid intake. Recurrent uric acid stone formation despite urinary alkalinization and increased hydration usually occurs in patients with high urinary uric acid excretion (exceeding 1000 mg/day [6 mmol/day]). However, xanthine oxidase inhibitor therapy is warranted in recurrent uric acid stone formers even if urinary uric acid excretion is in the reference range.


●Patients with gout – Patients with uric acid stones who also have recurrent or tophaceous gouty arthritis should be treated with a xanthine oxidase inhibitor for long-term control of gouty manifestations; the primary indication in such patients is gout and not necessarily the prevention of kidney stones (see "Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout"). Urate-lowering therapy for gout with uricosuric agents is not indicated as first-line therapy in gouty stone formers to prevent stone recurrence, as this will not lead to a long-term change in the amount of uric acid in the urine.

In a patient with a history of uric acid stones and gout but ≤1 flare of gouty arthritis per year, there may be no specific indication for xanthine oxidase inhibitor therapy. Rather, urinary alkalinization and increased hydration are the initial treatment option in such patients. If, however, the patient prefers a medication that could reduce both gout flare frequency and recurrence of uric acid stones, we would agree to prescribe treatment with a xanthine oxidase inhibitor (along with increased hydration but not necessarily urinary alkalinization).

Urinary alkalinization — The effect of increasing the urine pH on uric acid solubility can be appreciated from the Henderson-Hasselbalch equation for the relationship between soluble urate and insoluble uric acid, where 5.35 is functionally the pKa for this reaction under conditions existing in urine [31]:

pH = 5.35 + log ([urate] ÷ [uric acid])

At a urine pH of 6.75, more than 90 percent of the total urinary uric acid will be the more soluble urate salt, thereby minimizing the risk of uric acid precipitation.

There are no randomized trials that have evaluated the efficacy of urinary alkalinization on recurrence or dissolution of uric acid stones. However, alkalinization is associated with a remarkable reduction in recurrent stone episodes in observational studies. As an example, the mean rate of recurrent uric acid stones among 18 patients was reduced from 1.2 to 0.01 stones per patient per year with long-term treatment with potassium citrate [32]. Alkalinization can also dissolve existing uric acid calculi, as demonstrated in eight patients with recurrent uric acid stones who underwent serial ultrasound examinations after initiating potassium citrate or potassium bicarbonate [33].

鹼化尿液過度可能會造成磷酸鈣結石, 所以維持尿液 pH 6.5~7 即可, pH 超過 7 以上, 效果並沒有更好.
另外, 也不需要持續維持鹼化尿液, 一天一次或兩天一次, 將尿液pH提升超過 6.5 以上, 就可以預防尿酸結石產生. (不用 24 小時)
Alkalinization therapy should target a urine pH between 6.5 and 7. Achieving a urine pH higher than 7 will provide little if any further benefit on uric acid stone formation and may increase the risk of calcium phosphate stone formation (figure 1). An alkaline urine pH may not need to be maintained at all times since raising the urine pH to at least 6.5 once per day or every other day may prevent uric acid stone formation [34].

可給予重碳酸鉀 或檸檬酸鉀, 可將已經出現的腎結石溶解, 也可以預防腎結石生成, 使用鉀鹽比鈉鹽好. 因為檸檬酸鈉或重碳酸鈉會增加鈣的排泄(經腎臟), 在某些病患會引起鈣結石. 
應建議病患在家自己測尿液pH
Either potassium bicarbonate or potassium citrate can be given, with the typical dose being 40 to 80 mEq/day (table 2) [3,32]. This regimen can dissolve preexisting pure uric acid stones and prevent the formation of new stones. Alkalinization with potassium salts is preferable since the sodium load with sodium citrate or sodium bicarbonate may increase calcium excretion and promote the formation of calcium stones in some patients [32]. Patients should be instructed to check their urine pH at home; this will help guide the amount of alkali required.

運動比賽禁藥-非處方、營養補充品風險及運動禁藥處方臨床應用風險 (影片時間:47分43秒)

2026-08-08 20:15 醫師公會-醫師繼續教育(需登入會員才能看) 非處方、營養補充品風險及運動禁藥處方臨床應用風險   (影片時間:47分43秒) 藥物在體內移除